All Releases
 |
Optimer Pharmaceuticals Reports First Quarter 2008 Financial Results
May 7, 2008
|
12.6 KB |
| |
SAN DIEGO, May 07, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced its financial results for the first quarter ended March 31, 2008.
Optimer reported a net loss for the first quarter of 2008 of $7.9 million or, $0.28 per share. This compares to a net loss for the first quarter of 2007 of $24.5 million, or $1....
|
|
Optimer Pharmaceuticals to Present at Upcoming Investor Conferences
May 6, 2008
|
8.5 KB |
| |
SAN DIEGO, May 06, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced that the Company will present at the following investor conferences:
-- Bank of America 2008 Healthcare Conference on Thursday, May 15, 2008 at 8:30 a.m. Pacific Standard Time at the Four Seasons Hotel, Las Vegas.
-- Rodman & Renshaw 5th A...
|
|
Clostridium difficile Infection 'Epidemic' Leads to Calls for Emerging Next-Generation Therapies
Apr 21, 2008
|
12.9 KB |
| |
BARCELONA, Spain, Apr 21, 2008 (BUSINESS WIRE) -- Leading world experts in infectious disease have warned that the rapid spread of Clostridium difficile infection (CDI) has given rise to an epidemic, making it an urgent health priority.
The symposium, sponsored by Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR), at the 18th European Congress of Cli...
|
|
Optimer Pharmaceuticals Sponsors ECCMID Symposium on Clostridium Difficile-Associated Disease: Current Treatments and Challenges
Apr 15, 2008
|
13.6 KB |
| |
SAN DIEGO, Apr 15, 2008 (BUSINESS WIRE) -- Leading world experts in infectious disease will convene on Saturday, April 19th, to discuss the limitations of current and emerging therapies used to combat Clostridium difficile-associated disease (CDAD), also referred to as Clostridium difficile infection (CDI). CDI is recognized as the most common caus...
|
|
Optimer Pharmaceuticals Receives Notice of Allowance for OPT-80 Patent Application
Apr 8, 2008
|
8.7 KB |
| |
SAN DIEGO, Apr 08, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) has received a 'Notice of Allowance' on a US patent application from the United States Patent and Trademark Office protecting its lead drug candidate, OPT-80, which is being developed for the treatment of Clostridium difficile infection, or CDI. The pending paten...
|
|
Optimer Pharmaceuticals Announces Peer-Reviewed Publication of OPT-80 Phase 1 Clinical Results for the Treatment of Clostridium Difficile Infection
Apr 2, 2008
|
11.4 KB |
| |
SAN DIEGO, Apr 02, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the publication of its Phase 1 clinical trials of OPT-80 in the April 2008 edition of Antimicrobial Agents and Chemotherapy published by the American Society for Microbiology. The article is entitled, "Safety, Tolerance and Pharmacokinetic Studie...
|
|
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Mar 26, 2008
|
16.6 KB |
| |
SAN DIEGO, Mar 26, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced 2007 fourth quarter and full year financial results and accomplishments.
Optimer reported a net loss allocable to common stockholders for the three months ended December 31, 2007 of $7.0 million, or $0.27 per common share, as compared to a ne...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
Mar 19, 2008
|
8.7 KB |
| |
SAN DIEGO, Mar 19, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced it expects to report fourth quarter and full year 2007 financial results after the NASDAQ Global Market closes on Wednesday, March 26, 2008. The Company also expects to host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific T...
|
|
Optimer Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of Prulifloxacin in Patients with Travelers' Diarrhea
Mar 11, 2008
|
9.1 KB |
| |
SAN DIEGO, Mar 11, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company has completed enrollment in the first of two pivotal phase 3 clinical trials examining the safety and efficacy of prulifloxacin for the treatment of travelers' diarrhea. Travelers' diarrhea is characterized by diarrhea along with ...
|
|
Optimer Pharmaceuticals Awarded Grant from the National Institutes of Health for Development of OPT-80 to Treat Deadly Hospital Associated Infection
Jan 7, 2008
|
11.5 KB |
| |
SAN DIEGO, Calif., Jan 07, 2008 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) has been awarded a $1 million annual federal grant which will be applied to the late-stage development of OPT-80 to treat Clostridium difficile-Associated Diarrhea (C. difficile), or CDAD. C. difficile is a bacterial strain that can accumulate in the gut...
|
|
Optimer Appoints Anthony E. Altig to Board of Directors
Nov 28, 2007
|
9.1 KB |
| |
SAN DIEGO, Nov 28, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced that Anthony E. Altig has joined the company's Board of Directors and will be an active member of the company's audit and nominating and corporate governance committees.
"We are pleased to welcome Tony to our Board of Directors," said Michael ...
|
|
Optimer Pharmaceuticals to Present at the 19th Annual Piper Jaffray Health Care Conference
Nov 20, 2007
|
8.8 KB |
| |
SAN DIEGO, Nov 20, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the Company plans to present on Tuesday, November 27th during the 19th Annual Piper Jaffray Health Care Conference at The Pierre Hotel at 9:30 a.m. ET.
An audio webcast of the Piper Jaffray Conference will be available live and subsequent...
|
|
Optimer Pharmaceuticals Reports Third Quarter 2007 Financial Results
Nov 8, 2007
|
17.9 KB |
| |
SAN DIEGO, Nov 08, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced financial results for the third quarter and nine months ended September 30, 2007.
Optimer reported a net loss allocable to common stockholders for the third quarter of 2007 of $6.5 million or, $0.28 per common share, as compared to a net loss ...
|
|
Optimer to Present at Three Upcoming Investor Conferences
Oct 30, 2007
|
9.1 KB |
| |
SAN DIEGO, Oct 30, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that it plans to present at the following three investor conferences:
-- CIBC World Markets 18th Annual Healthcare Conference, Monday, November 5th, 2007 at 11:30 a.m. ET at the Waldorf-Astoria Hotel in New York City.
-- Acumen BioFin Rodm...
|
|
Optimer Announces $35.9 Million Private Placement
Oct 24, 2007
|
8.7 KB |
| |
SAN DIEGO, Oct 24, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced that it has entered into a securities purchase agreement with certain institutional investors to raise $35.9 million from the private placement of 4.6 million newly issued shares of its common stock, at a price of $7.80 per share. Subject to the s...
|
|
Leading Medical Experts Call for More Effective Strategies to Address Clostridium difficile-Associated Disease
Oct 8, 2007
|
12.3 KB |
| |
SAN DIEGO, Oct 08, 2007 (BUSINESS WIRE) -- Leading medical experts in the field of Clostridium difficile-Associated Disease or (CDAD), called for more effective strategies to prevent, rapidly diagnose and treat CDAD, according to presentations made during a symposium entitled "Clostridium Difficile-Associated Disease: Underdiagnosed, Underreported,...
|
|
Optimer Sponsors Symposium on Clostridium difficile-Associated Disease at Infectious Diseases Society of America (IDSA) Annual Meeting
Oct 1, 2007
|
11.4 KB |
| |
SAN DIEGO, Oct 01, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced that the company will sponsor a symposium focused on the identification, diagnosis, and treatment challenges of Clostridium difficile-Associated Disease (CDAD), a potentially severe form of infectious diarrhea, which results in an infection of the...
|
|
Optimer Presents Positive Data on Two Lead Anti-Infective Drug Candidates
Sep 20, 2007
|
10.5 KB |
| |
SAN DIEGO, Sep 20, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), presented data on the activity of its two lead compounds at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Earlier this week, data was presented at ICAAC showing that ulifloxacin, the active metabolite of prulifloxa...
|
|
Optimer to Present Data on Lead Antibiotic Candidates at ICAAC
Sep 13, 2007
|
10.0 KB |
| |
SAN DIEGO, Sep 13, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), today announced that results of a microbiologic study on the in vitro activity of OPT-80 and its primary metabolite, OP-1118, have been accepted at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held in Chicago, IL...
|
|
Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference
Aug 28, 2007
|
8.9 KB |
| |
SAN DIEGO, Aug 28, 2007 (BUSINESS WIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the Company is scheduled to present on Thursday, September 6, 2007, 10:30 a.m. EDT at the 2007 BioCentury NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY.
A live audio webcast of this present...
|
|
|
